Status:
COMPLETED
AlmegaPL CV Health Open Label Study
Lead Sponsor:
Qualitas Health
Collaborating Sponsors:
Arizona State University
Conditions:
Cholesterol
Triglycerides
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The aim of this study is to assess the effectiveness of Almega PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA), on improving blood markers associated with heart health ...
Detailed Description
The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic ac...
Eligibility Criteria
Inclusion
- New iwi/AlmegaPL subscribers.
Exclusion
- Participants that are already taking AlmegaPL.
- Participants with serious conditions including but not limited to kidney, neurological, immunological, liver and gastrointestinal disease, any heart condition or diabetes).
- Any participant attempting conception, pregnant or breastfeeding
Key Trial Info
Start Date :
May 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05267301
Start Date
May 11 2022
End Date
December 1 2022
Last Update
February 14 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona State University
Tempe, Arizona, United States, 85281
2
Qualitas Health
Houston, Texas, United States, 77057